Work

Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.3009

Authors: Michael B. Atkins, Toni K. Choueiri, F. Stephen Hodi, John A. Thompson, Wen-Jen Hwu, David F. McDermott, Melissa Brookes, Alessandra Tosolini, Scot Ebbinghaus, Zijiang Yang, Christine K. Gause, Rodolfo F. Perini, Antoni Ribas

Institutions: Georgetown Lombardi Comprehensive Cancer Center, Dana-Farber Cancer Institute, University of Washington, The University of Texas MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, Merck & Co., Inc., Rahway, NJ, USA (United States), University of California, Los Angeles

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2528359458

Cites:

Cited by: 29

Related to: 10